The Need for Centralization for Small Intestinal Neuroendocrine Tumor Surgery: A Cohort Study from the GTE-Endocan-RENATEN Network, the CentralChirSINET Study.


Journal

Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 24 04 2023
accepted: 22 08 2023
medline: 8 11 2023
pubmed: 10 10 2023
entrez: 9 10 2023
Statut: ppublish

Résumé

The concept of surgical centralization is becoming more and more accepted for specific surgical procedures. The aim of this study was to evaluate the relationship between procedure volume and the outcomes of surgical small intestine (SI) neuroendocrine tumor (NET) resections. We conducted a retrospective national study that included patients who underwent SI-NET resection between 2019 and 2021. A high-volume center (hvC) was defined as a center that performed more than five SI-NET resections per year. The quality of the surgical resections was evaluated between hvCs and low-volume centers (lvCs) by comparing the number of resected lymph nodes (LNs) as the primary endpoint. A total of 157 patients underwent surgery in 33 centers: 90 patients in four hvCs and 67 patients in 29 lvCs. Laparotomy was more often performed in hvCs (85.6% vs. 59.7%; p < 0.001), as was right hemicolectomy (64.4% vs. 38.8%; p < 0.001), whereas limited ileocolic resection was performed in 18% of patients in lvCs versus none in hvCs. A bi-digital palpation of the entire SI length (95.6% vs. 34.3%, p < 0.001), a cholecystectomy (93.3% vs. 14.9%; p < 0.001), and a mesenteric mass resection (70% vs. 35.8%; p < 0.001) were more often performed in hvCs. The proportion of patients with ≥8 LNs resected was significantly higher (96.3% vs. 65.1%; p < 0.001) in hvCs compared with lvCs, as was the proportion of patients with ≥12 LNs resected (87.8% vs. 52.4%). Furthermore, the number of patients with multiple SI-NETs was higher in the hvC group compared with the lvC group (43.3% vs. 25.4%), as were the number of tumors in those patients (median of 7 vs. 2; p < 0.001). Optimal SI-NET resection was significantly more often performed in hvCs. Centralization of surgical care of SI-NETs is recommended.

Sections du résumé

BACKGROUND BACKGROUND
The concept of surgical centralization is becoming more and more accepted for specific surgical procedures.
OBJECTIVE OBJECTIVE
The aim of this study was to evaluate the relationship between procedure volume and the outcomes of surgical small intestine (SI) neuroendocrine tumor (NET) resections.
METHODS METHODS
We conducted a retrospective national study that included patients who underwent SI-NET resection between 2019 and 2021. A high-volume center (hvC) was defined as a center that performed more than five SI-NET resections per year. The quality of the surgical resections was evaluated between hvCs and low-volume centers (lvCs) by comparing the number of resected lymph nodes (LNs) as the primary endpoint.
RESULTS RESULTS
A total of 157 patients underwent surgery in 33 centers: 90 patients in four hvCs and 67 patients in 29 lvCs. Laparotomy was more often performed in hvCs (85.6% vs. 59.7%; p < 0.001), as was right hemicolectomy (64.4% vs. 38.8%; p < 0.001), whereas limited ileocolic resection was performed in 18% of patients in lvCs versus none in hvCs. A bi-digital palpation of the entire SI length (95.6% vs. 34.3%, p < 0.001), a cholecystectomy (93.3% vs. 14.9%; p < 0.001), and a mesenteric mass resection (70% vs. 35.8%; p < 0.001) were more often performed in hvCs. The proportion of patients with ≥8 LNs resected was significantly higher (96.3% vs. 65.1%; p < 0.001) in hvCs compared with lvCs, as was the proportion of patients with ≥12 LNs resected (87.8% vs. 52.4%). Furthermore, the number of patients with multiple SI-NETs was higher in the hvC group compared with the lvC group (43.3% vs. 25.4%), as were the number of tumors in those patients (median of 7 vs. 2; p < 0.001).
CONCLUSIONS CONCLUSIONS
Optimal SI-NET resection was significantly more often performed in hvCs. Centralization of surgical care of SI-NETs is recommended.

Identifiants

pubmed: 37814184
doi: 10.1245/s10434-023-14276-8
pii: 10.1245/s10434-023-14276-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8528-8541

Informations de copyright

© 2023. Society of Surgical Oncology.

Références

de Mestier L, Lepage C, Baudin E, et al. Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis. 2020;52(5):473–92. https://doi.org/10.1016/j.dld.2020.02.011 .
doi: 10.1016/j.dld.2020.02.011 pubmed: 32234416
Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors, Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(7):839–68. https://doi.org/10.6004/jnccn.2021.0032 .
doi: 10.6004/jnccn.2021.0032 pubmed: 34340212
Keck KJ, Maxwell JE, Utria AF, et al. The distal predilection of small bowel neuroendocrine tumors. Ann Surg Oncol. 2018;25(11):3207–13. https://doi.org/10.1245/s10434-018-6676-2 .
doi: 10.1245/s10434-018-6676-2 pubmed: 30054825 pmcid: 6525566
Pasquer A, Walter T, Milot L, Hervieu V, Poncet G. Principles of surgical management of small intestinal NET. Cancers. 2021;13(21):5473. https://doi.org/10.3390/cancers13215473 .
doi: 10.3390/cancers13215473 pubmed: 34771639 pmcid: 8582489
Landry CS, Lin HY, Phan A, et al. Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors. World J Surg. 2013;37(7):1695–700. https://doi.org/10.1007/s00268-013-1918-8 .
doi: 10.1007/s00268-013-1918-8 pubmed: 23657749
Motz BM, Lorimer PD, Boselli D, Hill JS, Salo JC. Optimal lymphadenectomy in small bowel neuroendocrine tumors: analysis of the NCDB. J Gastrointest Surg. 2018;22(1):117–23. https://doi.org/10.1007/s11605-017-3524-9 .
doi: 10.1007/s11605-017-3524-9 pubmed: 28819895
Lardière-Deguelte S, de Mestier L, Appéré F, et al. Toward a preoperative classification of lymph node metastases in patients with small intestinal neuroendocrine tumors in the era of intestinal-sparing surgery. Neuroendocrinology. 2016;103(5):552–9. https://doi.org/10.1159/000441423 .
doi: 10.1159/000441423 pubmed: 26445315
Pasquer A, Walter T, Rousset P, et al. Lymphadenectomy during small bowel neuroendocrine tumor surgery: the concept of skip metastases. Ann Surg Oncol. 2016;23(S5):804–8. https://doi.org/10.1245/s10434-016-5574-8 .
doi: 10.1245/s10434-016-5574-8 pubmed: 27613554
Chen L, Song Y, Zhang Y, Chen M, Chen J. Exploration of the exact prognostic significance of lymphatic metastasis in jejunoileal neuroendocrine tumors. Ann Surg Oncol. 2018;25(7):2067–74. https://doi.org/10.1245/s10434-018-6511-9 .
doi: 10.1245/s10434-018-6511-9 pubmed: 29748891
Wang P, Chen E, Xie M, et al. The number of lymph nodes examined is associated with survival outcomes of neuroendocrine tumors of the jejunum and ileum (siNET): development and validation of a prognostic model based on SEER database. J Gastrointest Surg. 2022;26(9):1917–29. https://doi.org/10.1007/s11605-022-05359-0 .
doi: 10.1007/s11605-022-05359-0 pubmed: 35689008
Howe JR, Cardona K, Fraker DL, et al. The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017;46(6):715–31. https://doi.org/10.1097/MPA.0000000000000846 .
doi: 10.1097/MPA.0000000000000846 pubmed: 28609357 pmcid: 5502737
Pasquer A, Walter T, Hervieu V, et al. Surgical management of small bowel neuroendocrine tumors: specific requirements and their impact on staging and prognosis. Ann Surg Oncol. 2015;22(Suppl 3):742–9. https://doi.org/10.1245/s10434-015-4620-2 .
doi: 10.1245/s10434-015-4620-2
Vonlanthen R, Lodge P, Barkun JS, et al. Toward a consensus on centralization in surgery. Ann Surg. 2018;268(5):712–24. https://doi.org/10.1097/SLA.0000000000002965 .
doi: 10.1097/SLA.0000000000002965 pubmed: 30169394
El Amrani M, Clement G, Lenne X, et al. The impact of hospital volume and charlson score on postoperative mortality of proctectomy for rectal cancer: a nationwide study of 45,569 patients. Ann Surg. 2018;268(5):854–60. https://doi.org/10.1097/SLA.0000000000002898 .
doi: 10.1097/SLA.0000000000002898 pubmed: 30063493
Gooiker GA, Lemmens VEPP, Besselink MG, et al. Impact of centralization of pancreatic cancer surgery on resection rates and survival. Br J Surg. 2014;101(8):1000–5. https://doi.org/10.1002/bjs.9468 .
doi: 10.1002/bjs.9468 pubmed: 24844590
Pasquer A, Renaud F, Hec F, et al. Is centralization needed for esophageal and gastric cancer patients with low operative risk? A nationwide study. Ann Surg. 2016;264(5):823–30. https://doi.org/10.1097/SLA.0000000000001768 .
doi: 10.1097/SLA.0000000000001768 pubmed: 27429033
van Putten M, Nelen SD, Lemmens VEPP, et al. Overall survival before and after centralization of gastric cancer surgery in the Netherlands. Br J Surg. 2018;105(13):1807–15. https://doi.org/10.1002/bjs.10931 .
doi: 10.1002/bjs.10931 pubmed: 30132789
Noiret B, Clement G, Lenne X, et al. Centralization and oncologic training reduce postoperative morbidity and failure-to-rescue rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: study on a 10-year National French Practice. Ann Surg. 2020;272(5):847–54. https://doi.org/10.1097/SLA.0000000000004326 .
doi: 10.1097/SLA.0000000000004326 pubmed: 32833761
Kasai Y, Mahuron K, Hirose K, et al. Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors. J Surg Oncol. 2019;120(8):1311–7. https://doi.org/10.1002/jso.25727 .
doi: 10.1002/jso.25727 pubmed: 31613999
on behalf of the EORTC Quality of Life Group, Yadegarfar G, Friend L, et al. Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br J Cancer. 2013;108(2):301–10. https://doi.org/10.1038/bjc.2012.560 .
doi: 10.1038/bjc.2012.560
Fayers PM, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual: This Manual Is Intended to Assist Users with Scoring Procedures for the QLQ-C30 Version 3 and Earlier, and the QLQ Supplementary Modules. 3rd ed. EORTC; 2001.
Morin C, Benedetto KM, Deville A, et al. Management of neuroendocrine neoplasms: conformity with guidelines in and outside a center of excellence. Endocr Connect. 2022;11(6):e220097. https://doi.org/10.1530/EC-22-0097 .
doi: 10.1530/EC-22-0097 pubmed: 35521801 pmcid: 9254288
Sundin A, Arnold R, Baudin E, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging. Neuroendocrinology. 2017;105(3):212–44. https://doi.org/10.1159/000471879 .
doi: 10.1159/000471879 pubmed: 28355596
Kaçmaz E, Chen JW, Tanis PJ, Nieveen van Dijkum EJM, Engelsman AF. Postoperative morbidity and mortality after surgical resection of small bowel neuroendocrine neoplasms: a systematic review and meta-analysis. J Neuroendocrinol. 2021;33(8):e13008. https://doi.org/10.1111/jne.13008 .
doi: 10.1111/jne.13008 pubmed: 34235792 pmcid: 8459236
Balzano G, Guarneri G, Pecorelli N, et al. Modelling centralization of pancreatic surgery in a nationwide analysis. Br J Surg. 2020;107(11):1510–9. https://doi.org/10.1002/bjs.11716 .
doi: 10.1002/bjs.11716 pubmed: 32592514
El Amrani M, Lenne X, Clement G, et al. Specificity of procedure volume and its association with postoperative mortality in digestive cancer surgery: a nationwide study of 225,752 patients. Ann Surg. 2019;270(5):775–82. https://doi.org/10.1097/SLA.0000000000003532 .
doi: 10.1097/SLA.0000000000003532 pubmed: 31498184
Elamrani M, Clément G, Lenne X, et al. Should all pancreatic surgery be centralized regardless of patients’ comorbidity? HPB. 2020;22(7):1057–66. https://doi.org/10.1016/j.hpb.2019.10.2443 .
doi: 10.1016/j.hpb.2019.10.2443
Hata T, Motoi F, Ishida M, et al. Effect of hospital volume on surgical outcomes after pancreaticoduodenectomy: a systematic review and meta-analysis. Ann Surg. 2016;263(4):664–72. https://doi.org/10.1097/SLA.0000000000001437 .
doi: 10.1097/SLA.0000000000001437 pubmed: 26636243
Farges O, Bendersky N, Truant S, Delpero JR, Pruvot FR, Sauvanet A. The theory and practice of pancreatic surgery in France. Ann Surg. 2017;266(5):797–804. https://doi.org/10.1097/SLA.0000000000002399 .
doi: 10.1097/SLA.0000000000002399 pubmed: 28885506
van Heek NT, Kuhlmann KFD, Scholten RJ, et al. Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in The Netherlands. Ann Surg. 2005;242(6):781–90. https://doi.org/10.1097/01.sla.0000188462.00249.36 .
doi: 10.1097/01.sla.0000188462.00249.36 pubmed: 16327488 pmcid: 1409869
O’Kane D, Papa N, Lawrentschuk N, Syme R, Giles G, Bolton D. Supervisor volume affects oncological outcomes of trainees performing open radical prostatectomy: oncological outcomes by surgeon volume. ANZ J Surg. 2016;86(4):249–54. https://doi.org/10.1111/ans.13112 .
doi: 10.1111/ans.13112 pubmed: 25916513
Gray AC, Fearon PV, Gregory R. Major trauma centres and trauma networks—the potential impact on surgical training. Injury. 2015;46(2):176–7. https://doi.org/10.1016/j.injury.2015.01.023 .
doi: 10.1016/j.injury.2015.01.023 pubmed: 25697734
Le Roux C, Lombard-Bohas C, Delmas C, et al. Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study. Dig Liver Dis. 2011;43(10):828–33. https://doi.org/10.1016/j.dld.2011.04.021 .
doi: 10.1016/j.dld.2011.04.021 pubmed: 21641888
Kim MK, Warner RRP, Ward SC, et al. Prognostic significance of lymph node metastases in small intestinal neuroendocrine tumors. Neuroendocrinology. 2015;101(1):58–65. https://doi.org/10.1159/000371807 .
doi: 10.1159/000371807 pubmed: 25572143

Auteurs

Maroin Kalifi (M)

Department of Digestive Surgery, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon Cedex 03, France.

Sophie Deguelte (S)

Department of Digestive Surgery, Reims University Hospital, Robert Debré Hospital, Reims, France.

Matthieu Faron (M)

Departments of Surgical Oncology and Statistics, Gustave Roussy Cancer Campus® Grand Paris, Villejuif, France.

Pauline Afchain (P)

Department of Oncology, CHU Saint-Antoine, APHP, Paris, France.

Louis de Mestier (L)

Department of Pancreatology and Digestive Oncology, ENETS Centre of Excellence, Beaujon Hospital (APHP Nord), Université Paris-Cité, Clichy, France.

Thierry Lecomte (T)

Department of Hepato-Gastroenterology and Digestive Oncology, University Hospital of Tours, UMR INSERM 1069, Tours University, Tours, France.

Arnaud Pasquer (A)

Department of Digestive Surgery, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon Cedex 03, France.

Fabien Subtil (F)

Gastroenterology and Technologies for Health, Research Unit INSERM UMR 1052 CNRS UMR 5286, Cancer Research Center of Lyon, Lyon, France.
Department of Biostatistic, Hospices Civils de Lyon, Lyon, France.

Khalid Alghamdi (K)

King Abdulaziz University, Jeddah, Saudi Arabia.

Gilles Poncet (G)

Department of Digestive Surgery, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon Cedex 03, France. gilles.poncet@chu-lyon.fr.
Gastroenterology and Technologies for Health, Research Unit INSERM UMR 1052 CNRS UMR 5286, Cancer Research Center of Lyon, Lyon, France. gilles.poncet@chu-lyon.fr.
Université de Lyon, Université Claude Bernard Lyon 1, Villeurbanne Cedex, France. gilles.poncet@chu-lyon.fr.
Pavillon D, Chirurgie Digestive, Hôpital Edouard Herriot, Lyon Cedex 03, France. gilles.poncet@chu-lyon.fr.

Thomas Walter (T)

Department of Gastroenterology and Digestive Oncology, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon Cedex 03, France.
Gastroenterology and Technologies for Health, Research Unit INSERM UMR 1052 CNRS UMR 5286, Cancer Research Center of Lyon, Lyon, France.
Université de Lyon, Université Claude Bernard Lyon 1, Villeurbanne Cedex, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH